{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T08:00:24Z","timestamp":1780992024624,"version":"3.54.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.clml.2025.12.002","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T16:50:25Z","timestamp":1765471825000},"page":"e397-e407","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Improved Outcomes Following the Adoption of Targeted Therapies in High-Risk Chronic Lymphocytic Leukemia Treated in Southern Finland"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4562-9606","authenticated-orcid":false,"given":"Tuija","family":"Tapaninen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5724-9120","authenticated-orcid":false,"given":"Vesa","family":"Lindstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8260-3356","authenticated-orcid":false,"given":"Olivia","family":"H\u00f6ls\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7626-8368","authenticated-orcid":false,"given":"Emma-Leena","family":"Alarmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liisa","family":"Ukkola-Vuoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimmo","family":"Porkka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7842-9419","authenticated-orcid":false,"given":"Oscar","family":"Br\u00fcck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.12.002_bib0001","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2025.12.002_bib0002","series-title":"Cancer Statistics","year":"2025"},{"key":"10.1016\/j.clml.2025.12.002_bib0003","series-title":"FIfHa Welfare, ed. Finnish Cancer Registry","article-title":"Cancer in Finland 2019","author":"Pitk\u00e4niemi","year":"2021"},{"key":"10.1016\/j.clml.2025.12.002_bib0004","series-title":"Finnish Cancer Registry","article-title":"Cancer in Finland 2021","author":"Sepp\u00e4","year":"2023"},{"key":"10.1016\/j.clml.2025.12.002_bib0005","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13102468","article-title":"Current treatment options in CLL","author":"Bewarder","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2025.12.002_bib0006","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","article-title":"ESMO Clinical Practice Guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia","volume":"35","author":"Eichhorst","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2025.12.002_bib0007","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.12.002_bib0008","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/leu.2012.25","article-title":"ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia","volume":"26","author":"Pospisilova","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.12.002_bib0009","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1038\/s41375-024-02267-x","article-title":"ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 update","volume":"38","author":"Malcikova","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.12.002_bib0010","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/leu.2017.125","article-title":"Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations","volume":"31","author":"Rosenquist","year":"2017","journal-title":"Leukemia"},{"issue":"Suppl 2","key":"10.1016\/j.clml.2025.12.002_bib0011","first-page":"S3","article-title":"Management of front line chronic lymphocytic leukemia","volume":"97","author":"Kutsch","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.12.002_bib0012","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000533704","article-title":"Prognostic markers in the era of targeted therapies","volume":"147","author":"Kang","year":"2024","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2025.12.002_bib0013","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/s41467-023-37648-w","article-title":"Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia","volume":"14","author":"Al-Sawaf","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.clml.2025.12.002_bib0014","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1182\/blood.2023021959","article-title":"Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL","volume":"143","author":"Woyach","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.12.002_bib0015","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.12.002_bib0016","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/ejh.13273","article-title":"Observational evidence from patients diagnosed with chronic lymphocytic leukaemia (CLL) in Finland between 2005 and 2015 show improved survival over time","volume":"103","author":"Lindstr\u00f6m","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2025.12.002_bib0017","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/jha2.322","article-title":"Characterization of real-world treatment practices and outcomes among patients with chronic lymphocytic leukemia treated in a Finnish tertiary center","volume":"3","author":"Ranti","year":"2022","journal-title":"EJHaem"},{"key":"10.1016\/j.clml.2025.12.002_bib0018","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/ejh.13743","article-title":"Identifying patients with chronic lymphocytic leukemia without need of treatment: end of endless watch and wait?","volume":"108","author":"Brieghel","year":"2022","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2025.12.002_bib0019","doi-asserted-by":"crossref","first-page":"5698","DOI":"10.1182\/bloodadvances.2021006259","article-title":"CLL-IPI applied in Binet A CLL: a nationwide cohort study","volume":"6","author":"Rotbain","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2025.12.002_bib0020","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1111\/bjh.18715","article-title":"Real-world outcomes upon second-line treatment in patients with chronic lymphocytic leukaemia","volume":"201","author":"Vainer","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.12.002_bib0021","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.3324\/haematol.2019.220194","article-title":"IGHV mutational status and outcome for patients with chronic lymphocytic leukemia upon treatment: a Danish nationwide population-based study","volume":"105","author":"Rotbain","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.12.002_bib0022","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/ejh.13499","article-title":"Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib","volume":"105","author":"Aarup","year":"2020","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2025.12.002_bib0023","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/jha2.174","article-title":"Real-world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK","volume":"2","author":"Hillmen","year":"2021","journal-title":"EJHaem"},{"key":"10.1016\/j.clml.2025.12.002_bib0024","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"Am J Epidemiol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042971?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042971?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T07:44:35Z","timestamp":1780991075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025042971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2152265025042971"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.12.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improved Outcomes Following the Adoption of Targeted Therapies in High-Risk Chronic Lymphocytic Leukemia Treated in Southern Finland","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}